Plays event-driven biotech, swing trades big board stocks and loves research and DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMRN - to get the same level of upside, I would have to put up much more capital. Decided not to do that.
AMRN - Jan 2013 $10 calls. Averaged in around 2.20.
AIS - the most vague PR I have ever seen. Still holding shares short :
Antares announces licensing agreement with Pfizer
Antares Pharma (AIS) announced that it has licensed to Pfizer�s (PFE) Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares will receive undisclosed upfront payments, development milestones and sales based milestones, as well as royalties on net sales for three years post launch in the US
Good points by both of you. The over ridding issue remains the lack of economic growth, both here and in Europe. Even if the ECB could do a US-style QE and monitize the debt, it would likely just be a band-aid.
As for our growth, let's hope the Q4 earnings and guidance are strong.
Are you sure the debt levels are lower on a relative basis? Relative to GDP? I haven't looked at that.
I hope you are correct. You do live in Europe, so you have a different and better perspective than the talking heads over here.
Agree to an extent. Part of the reason I am accumulating AMRN Leaps. Would love to see a more concrete resolution in Europe, but I just don't think it exists.
SPY - yet another gap up today based upon German confidence numbers and lower Italian bond yields. I also think this will be faded.
Bottom line is Europe will continue to be drag on the markets. Worse still is there is no real resolution. The ECB cannot do a US-style QE and there is no economic growth in the PIIGS.
The US is doing somewhat better, but the real tell will be Q4 earnings and I don't think they will show the same growth as they did in previous quarters.
In short, no compelling reason to buy stocks.
SPY - looks like yet another fade the gap day. Futes and SPY bleeding down all morning.
SOMX - Halted FWIW...
PCYC - Pharmacyclics receives issue notice of significant BTK patent
Pharmacyclics announced issue notification from the U.S. Patent & Trademark Office, or USPTO, of a patent entitled "Inhibitors of Bruton's Tyrosine Kinase" and specifically claiming "an inhibited tyrosine kinase comprising an irreversible BTK inhibitor having a covalent bond to a cysteine residue of a Bruton's tyrosine kinase, or BTK". This U.S. patent 8,088,781 is set to issue on January 3, 2012.
INHX - Inhibitex market overreaction a buying opportunity, says Canaccord
Canaccord would be aggressive buyers of Inhibitex (INHX) due to the overreaction in shares following Pharmasset's (VRUS) PSI-938 clinical developments. The firm does not believe similarities between '938 and Inhibitex's INX-189 products should predict INX-189 longer term dosing toxicity profile. Share are Buy rated with a $22 price target.
SQNM - Sequenom's CMM for MaterniT21 LDT ordered by U.S. healthcare providers
Sequenom announced that numerous leading healthcare providers across the U.S., including Women & Infants Hospital of Rhode Island, Vanderbilt University Medical Center, and Florida Hospital in Orlando have begun ordering the Sequenom Center for Molecular Medicine's, or Sequenom CMM, MaterniT21 laboratory-developed test, or LDT, for their patients. The MaterniT21 LDT provides direct assessment of fetal chromosomal status by examining circulating cell-free DNA in a maternal blood sample
AMRN - as I posted yesterday...tax loss selling. I should have considered this first before buying the Jan 13 leaps.
YMI - they didnt list one
AIS - shorted at $1.85.
AIS - YM Biosciences valuation attractive, says Roth Capital
Roth Capital believes that YM Biosciences is well-positioned to sign a major partnership deal in 1H12, and the firm doesn't think that the differentiated CYT387 myelofibrosis data at ASH has been priced into the stock. The firm thinks that YM is a "compelling story," and it reiterates a Buy rating
BPAX - why I took the money and ran at the pre mkt open.
DECK - taken to the woodshed on downgrade. Down 8% pre mkt.
AIS - on short watch if it gets close to $2.00
BPAX - out for a quick 25% gain.
BPAX - all news so far:
BioSante downgraded to Market Perform from Outperform at Rodman & Renshaw
Rodman & Renshaw downgraded BioSante citing the failure of LibiGel to achieve any of its endpoints in two Phase 3 trials. :theflyonthewall.com
07:31 EDT BPAX
theflyonthewall.com: Put option volume increases
Put option volume increases according to Bloomberg are: BCS NG BPAX ARMH. :theflyonthewall.com
07:30 EDT BPAX
theflyonthewall.com: Call option volume increases
Call option volume increases according to Bloomberg are: GFI VRTX BPAX VRX. :theflyonthewall.com
07:23 EDT BPAX
theflyonthewall.com: BioSante downgraded to Market Perform from Outperform at Leerink
Leerink downgraded BioSante after the company's Phase III BLOOM trials failed to show a statistically significant separation from placebo. The firm lowered its fair value estimate for shares to 11c from $6. :theflyonthewall.com
07:06 EDT BPAX
theflyonthewall.com: BioSante implied volatility elevated
BioSante option implied volatility is near the top of its 52-week range according to iVolatility. :theflyonthewall.com
06:38 EDT BPAX
theflyonthewall.com: BioSante downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded BioSante due to the negative Ph III trial results for LibiGel. Price target cut to $2. :theflyonthewall.com
05:59 EDT BPAX
theflyonthewall.com:
BPAX - I have seen targets of $2 and 11¢
BPAX - the sell off was an overreaction, as they usually are. Plus a lot of the float is short, so the shorts will cover - with an 80% + gain, they should!
Not so sure about the long term prospects of the company, but the short term should see a bounce.
BPAX - great attitude! Yeah, that is quite a haircut. I hope folks did not put a lot of risk into this one.
BPAX - thanks. Hope I am right. Purely playing the short covering.
BPAX - I expect the short covering to push this to .60-.70 tomorrow.
BPAX - sorry bro. The sell off was brutal. I checked AH and couldn't believe it. Hang in there and better luck next time!
BPAX - grabbed 3000 shrs at 50¢ for a trade only. I think cash per share is 68¢
NGSX- FDA posts warning letter sent to NeurogesX for Qutenza exhibit
The Office of Prescription Drug Promotion of the FDA said in a letter that it has reviewed an exhibit booth for Qutenza submitted by NeurogesX. The FDA said the exhibit booth is "false or misleading because it presents efficacy claims for Qutenza but fails to communicate information about the risks associated with its use." The FDA requested that NeurogesX immediately cease the dissemination of violative promotional materials for Qutenza
AMRN - tax loss selling in full effect
OT: EUR < 1.30, GOLD tanking. EZ downgrades imminent! Happy Wednesday Everyone!
ALL EUROPE ALL THE TIME. As Brad Hamilton said, "learn it, know it, live it."
Showing my age :)
NGSX - likely tax loss selling
YMI - sold some last nite. Still holding. May add here...watching.
ALXA - thanks. Too easy. Just covered @.86 for a 16% gain. Now wtf is going on with YMI. LOL!
YMI - YM Biosciences data encouraging, says Wells Fargo
After YM announced data for its CYT387 Jak inhibitor, Wells Fargo views the data as solid and recommends buying the stock on strength
ALXA - short at $1.06
$YMI panic retail profit taking pre market. Shelf fear IMO.
Ameritrade does not allow pre mkt orders til after 8am
NFLX - Verizon "very serious" about Netflix bid, Bloomberg reports
According to Porter Bibb of MediaTech Capital, there are "rumblings from inside Verizon (VZ) that they are very serious about either Netflix (NFLX) or something similar", and a bidding war could lead to the company's sale for around $4.6B by Easter, according to Bloomberg. Reference Link :theflyonthewall.com